Form 4: Adaptive Biotechnologies CPO Sells Shares
Insider Transaction Report
Adaptive Biotechnologies' Chief People Officer, Francis Lo, exercised stock options and subsequently sold 4,394 shares of common stock on December 22, 2025, under a Rule 10b5-1 trading plan.
Summary
- Francis Lo, Chief People Officer of Adaptive Biotechnologies Corp (ADPT), engaged in transactions involving the company's common stock.
- The transactions occurred on December 22, 2025, and were executed pursuant to a Rule 10b5-1 trading plan adopted on September 15, 2025.
- Lo exercised stock options to acquire 1,100 shares at $7.80 per share, 2,194 shares at $8.46 per share, and 1,100 shares at $3.99 per share.
- A total of 4,394 shares of common stock were sold at a weighted-average price of $17.50 per share, with individual sales ranging from $17.49 to $17.50.
- Following these reported transactions, Francis Lo directly beneficially owns 315,978 shares of common stock and indirectly owns 2,500 shares through You Jin Lee (spouse).
Sentiment
Score: 6
Explanation: The filing reports an insider exercising options and selling shares for a profit, which is a neutral to slightly positive signal for the insider's personal financial gain. For the company, it's a routine insider transaction under a pre-arranged plan, so it doesn't inherently convey strong positive or negative sentiment about the company's future prospects.
Positives
- The insider realized a significant profit by exercising options at lower prices ($3.99, $7.80, $8.46) and selling the shares at a higher weighted-average price of $17.50.
- Transactions were conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned disposition rather than a reactive or opportunistic sale based on immediate non-public information.
Negatives
- An insider sale, even under a 10b5-1 plan, could be interpreted by some investors as a signal that the insider does not expect significant short-term appreciation in the stock price, though this is not a definitive conclusion.
Future Outlook
NA
Industry Context
NA
Stakeholder Impact
- Shareholders: May observe an insider selling shares, which could be interpreted in various ways, though the 10b5-1 plan mitigates concerns about opportunistic selling based on non-public information.
Key Dates
| Date | Description |
|---|---|
| 2024-03-04 | Vesting date for 1/4 of certain stock options, with subsequent monthly vesting. |
| 2025-03-04 | Vesting date for 1/4 of certain stock options, with subsequent monthly vesting. |
| 2025-09-15 | Date the Rule 10b5-1 trading plan was adopted by the reporting person. |
| 2025-12-22 | Date of stock option exercises and common stock sale transactions. |
| 2025-12-29 | Signature date of the Form 4 filing. |
| 2029-05-06 | Expiration date for a stock option with an exercise price of $7.80. |
| 2033-03-06 | Expiration date for a stock option with an exercise price of $8.46. |
| 2034-03-04 | Expiration date for a stock option with an exercise price of $3.99. |
Keywords
Adaptive Biotechnologies, ADPT, Form 4, Insider Trading, Stock Option Exercise, Share Sale, Francis Lo, Chief People Officer, Rule 10b5-1
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.